The effects of the second generation antipsychotics and a typical neuroleptic on collagen-induced platelet aggregation in vitro

References

• Abrams CS, Brass LF. Platelet signal transduction. Hemostasis and thrombosis, basic principles and clinical practice, RW Colman, J Hirsh, VJ Marder, AW Clowes, JN George. Lippincott Williams and Wilhins. Chapter 31, Philadelphia, PA 2001; 541–559
   Google Scholar
• Allebeck P. Schizophrenia: A life-shortening illness. Schizophr Bull 1989; 15: 81–89
   PubMed Web of Science ®Google Scholar
• Allebeck P, Wistedt B. Mortality in schizophrenia a ten-year follow-up based on the: Stockholm Country inpatient register. Arch Gen Psychiatry 1986; 43: 650–653
   PubMedGoogle Scholar
• Bakken AM, Staeffler A, Jorgensen HA, Holmsen H. Glycerophospholipid molecular species in platelets and brain tissues – are platelets a good model for neurons?. Platelets 2006; 17: 484–492
   PubMed Web of Science ®Google Scholar
• Berk M, Plein H, Czismadia T. Super – sensitive platelet glutamate receptors as a possible peripheral marker in schizophrenia. Int Clin Psychopharmaced 1999; 14: 119–122
   PubMed Web of Science ®Google Scholar
• Blockmans D, Deckmyn H, Vermylen J. Platelet activation. Blood Rev 1995; 9: 143–156
   PubMed Web of Science ®Google Scholar
• Boullin DJ, Know JM, Peters JR, Orr MW, Gelder MG, Grahame-Smith DG. Platelet aggregation and chlorpromazine therapy. Br J Clin Pharmacol 1978; 6: 538–540
   PubMedGoogle Scholar
• De Clerck F, Somers Y, Mannaert E, Greenspan A, Eerdekens M. Greenspan A, Eerdekens M. In vitro effects of risperidone and 9-hydroxy0risperidone on human platelet function, plasma coagulation, and fibrynolysis. Clin Ther 2004; 26: 1261–1273
   PubMed Web of Science ®Google Scholar
• Dietrich-Muszalska A. Evaluation of the effects of different concentrations of risperidone, corresponding to the drug doses used in treatment of schizophrenic patients, on lipid peroxidation in plasma and blood platelets at in vitro studies. Psychiatr Psychol Klin 2004; 4: 215–223
   Google Scholar
• Dietrich-Muszalska A, Olas B. Isoprostanes as indicators of oxidative stress in schizophrenia. World J Biol Psychiatry 2007; 8: 1–7
   Google Scholar
• Dietrich-Muszalska A, Rabe-Jablonska J, Zgirski A. The effects of olanzapine (Zolafren) on lipid peroxidation in human blood platelets and plasma: In vitro studies. Psychiatr Psychol Klin 2004; 4: 13–19
   Google Scholar
• Dietrich-Muszalska A, Olas B, Rabe-Jablonska J. Oxidative stress in blood platelets from schizophrenic patients. Platelets 2005; 16: 386–391
   PubMed Web of Science ®Google Scholar
• Dinan TG. Neuroleptic effects on platelet aggregation: A study in normal volunteers and schizophrenics. Psychol Med 1987; 17: 875–881
   PubMed Web of Science ®Google Scholar
• Eerdekens M, Hove IV, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizoph Res 2007; 70: 91–100
   Google Scholar
• Ertugrul A, Ucar G, Basar K, Demir B, Yabanoglu S, Ulug B. Influence of clozapine on platelet serotonin, monoamine oxidase and plasma serotonin levels. Psychiatr Res 2007; 149: 49–57
   PubMedGoogle Scholar
• Frolich KW, Aarbakke GM, Holmsen H. Chlorpromazine increases the turnover of metabolically active phosphoinositides and elevates the steady-state level of phosphatidylinositol-4-phosphate in human platelets. Biochem Pharmacol 1992; 44: 2013–2020
   PubMedGoogle Scholar
• Hagg S, Spiegset O, Soderstrom TG. Association of venous thromboembolism and clozapine. Lancet 2000; 355: 1155–1156
   PubMed Web of Science ®Google Scholar
• Ishigooka J, Shizu Y, Wakatabe H, Tanaka K, Miura S. Different effects of centrally acting drugs on rabbit platelet aggregation: With special reference to selective inhibitiory effects of antipsychotics and antidepressants. Biol Psychiatry 1985; 20: 866–873
   PubMedGoogle Scholar
• Jeding I, Evans PJ, Akanmu D, Dexter D, Spencer JD, Arunoma OI, et al. Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochem Pharmacol 1995; 49: 359–365
   PubMed Web of Science ®Google Scholar
• Klawans HL, Goetz GC, Perlik S. Tardive dyskinesia: Review and update. Am J Psychiatry 1980; 137: 900–908
   PubMed Web of Science ®Google Scholar
• Laasvatn KO, Holmsen H. Chlorpromazine and human platelet glycerolipid metabolism: Precursor specificity and significance of drug-platelet interaction time. Biochem Pharmacol 1999; 57: 1113–1123
   PubMedGoogle Scholar
• Levy-Toledano S. Platelet signal transduction pathways: Could we organize them into a hierarchy?. Haemostas 1999; 29: 4–15
   PubMedGoogle Scholar
• Lohr JB, Kuczenski R, Bracha HS, Moir M, Jeste DV. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesi. Biol Psychiatry 1990; 28: 535–539
   PubMed Web of Science ®Google Scholar
• Magos T. Monoaminergic influence on the visual evoked potentials (VEP). Recent Advances in Human Neurophysiology 1998; 1: 455–465
   Google Scholar
• Magos T. Correlation between platelet monoamine oxidase activity and the strength of a visual illusion. Vision Res 2001; 41: 31–35
   Google Scholar
• McNicol A. Platelet preparation and estimation of functional responses. Platelets. A practical approach, SP Watson, KS Authi. Oxford University Press, Oxford, New York, Tokyo 1995; 1–6
   Google Scholar
• Murphy DL, Donnelly CH. Monamine oxidase in man: Enzyme characteristics in platelets, plasma, and other human tissues. Adv Biochem Psychopharmacol 1974; 12: 71–85
   PubMedGoogle Scholar
• Nowak P, Wachowicz B. Peroxynitrite-mediated modification of fibrinogen affects platelet aggregation and adhesion. Platelets 2002; 13: 293–299
   PubMed Web of Science ®Google Scholar
• Numata S, Kato O, Misawa H, Tokuda H, Kasahara T, Ohmori T. Left atrial thrombosis associated with antipsychotic drugs. Progr Neuro-Psychopharmacol Biolog Psychiatry 2005; 9: 153–155
   Google Scholar
• Pall HS, Williams AC, Blake DR, Lunec J. Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet 1987; 12: 596–599
   Google Scholar
• Peet M, Laugharne J, Rangarajan N, Reynolds GP. Tardive dyskinesia, lipid peorxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychophamacol 1993; 8: 151–153
   PubMed Web of Science ®Google Scholar
• Plein H, Berk M. The platelet as a peripheral marker in psychiatric illness. Human Psychopharmacol Clin Exp 2001; 16: 229–236
   PubMed Web of Science ®Google Scholar
• Reddy R, Keshavan M, Yao JK. Blunted serotonergic responsivity in neurolrptic-naïve patients at first-episode of schizophrenia. Schizophr Res 2007; 90: 8105
   Google Scholar
• Ricci A, Bronzetti E, Mannino F, Mignini F, Morosetti C, Tayebati S, et al. Dopamine receptors in human platelets. Naunyn-Schmiedeberg's. Arch Pharmacol 2003; 363: 376–382
   Google Scholar
• Ryningen A, Holmsen H. Platelet physiology and pharmacology, H Gundu, R Rao. Kluwer Academic Publishers, Norwell, MA 1999; 1–22
   Google Scholar
• Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J Neurochem 1998; 71: 1002–1012
   PubMed Web of Science ®Google Scholar
• Szabo L, Lajko K, Barabas K, Matkovics B. Effects of neuroleptics on lipid peroxidation and peroxide metabolism enzyme activities in various discrete areas of the rat brain. Chem Pharmacol 1983; 14: 537–539
   Google Scholar
• Taylor D, Paton C, Kerwin R. The South London and Maudsley NHS Trust. Prescribing Guidelines7th Edition. Martin Dunitz, Taylor & Francis Group London and New York. 2003
   Google Scholar
• The United States Pharmacopoeia Drug Information. Drug Information for the Health Care Professional. Vol I20th ed. Thomson Micromedex, Greenwood Village 2000
   Google Scholar
• Von Kanel R. Platelet hyperactivity in clinical depression and the beneficial effect of antidepressant drug treatment: How strong is the evidence?. Acta Psychiatr Scand 2004; 110: 163–177
   PubMed Web of Science ®Google Scholar
• Walsh MT, Ryan M, Hillmann A, Condren R, Kenny D, Dinan T, et al. Elevated expression of integrin αIIbβIIIa in drug-naïve, first-episode schizophrenic patients. Biol Psychiatry 2002; 52: 874–879
   PubMed Web of Science ®Google Scholar
• Wu K. Platelet activation mechanisms and marker in arterial thrombosis. J Inter Med 1996; 239: 17–34
   PubMed Web of Science ®Google Scholar
• Yang J, Wu J, Kowalska MA, Dalvi A, Prevost N, O' Brien PJ, et al. Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs. Proc Natl Acad Sci USA 2000; 97: 9984–9999
   PubMed Web of Science ®Google Scholar
• Yang TY, Chung KJ, Huang TL, Kung CT. Massive pulmonary embolism in a young patient on clozapine therapy. J Emergency Med 2004; 27: 27–29
   PubMed Web of Science ®Google Scholar
• Yao JK, van Kammen DP, Gurklis J, Peters JL. Platelet aggregation and dense granule secretion in schizophrenia. Psychiatry Res 1994; 54: 13–24
   PubMed Web of Science ®Google Scholar
• Zornberg GL, Jick H. Antipsychotic drug and risk of first-time idiopathic venous thromboembolism: A case-control study. Lancet 2000; 356: 1219–1223
   PubMed Web of Science ®Google Scholar